Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

April 1, 2042

Conditions
Leukemia, Myeloid, AcuteLeukemia, B-cellLeukemia, T-Cell
Interventions
BIOLOGICAL

Treatment Arm A

"Each patient will receive one T cell infusion.~CD70.CAR Dose Levels / Cell Dose (transduced cells):~Dose Level -1: 3 x 10\^5 cells/kg Dose Level 1 (starting dose level): 1 x 10\^6 cells/kg Dose Level 2: 3 x 10\^6 cells/kg Dose Level 3: 1 x 10\^7 cells/kg~\*First three patients treated on the study will be adults 18 years of age or older."

Trial Locations (2)

77030

Texas Children's Hospital, Houston

The Methodist Hospital, Houston

All Listed Sponsors
lead

Baylor College of Medicine

OTHER